{"entity":{"id":"low-pv","kind":"trial","name":"Low-PV","aka":[],"tldr":"Low-PV asked whether even low-risk patients gain from interferon: more of them stayed at the haematocrit target without progression when ropeginterferon was added to phlebotomy.","summary":"Low-PV randomised 127 patients with low-risk PV (under 60 with no prior thrombosis) to phlebotomy plus low-dose aspirin with or without ropeginterferon alfa-2b. At 12 months, 84 percent on ropeginterferon kept a haematocrit at or below 45 percent without progressive disease versus 60 percent with phlebotomy alone (Barbui and colleagues, Lancet Haematology 2021), with fewer phlebotomies and no excess serious harm; the benefit held at two years.","status":"positive","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03003325","url":"https://clinicaltrials.gov/study/NCT03003325"}],"tags":["polycythaemia-vera","mpn"],"related":[],"cancers":["polycythaemia-vera"],"sections":[],"technologies":[],"targets":[],"drugs":["ropeginterferon-alfa-2b"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03003325","phase":"2","setting":"Low-risk polycythaemia vera: ropeginterferon alfa-2b plus phlebotomy versus phlebotomy alone","sponsor":"FROM Research Foundation, Bergamo","result":"Haematocrit at or below 45% without progression at 12 months: 84% vs 60%.","yearReported":2021,"enrolled":127,"outcomes":[{"endpoint":"Response at 12 months","primary":true,"unit":"%","arms":[{"name":"Ropeginterferon + phlebotomy","n":64,"value":84},{"name":"Phlebotomy alone","n":63,"value":60}]}]},"route":"/trials/low-pv/","neighbours":{"cancer":[{"id":"polycythaemia-vera","kind":"cancer","name":"Polycythaemia vera (PV)","route":"/cancers/polycythaemia-vera/"}],"drug":[{"id":"ropeginterferon-alfa-2b","kind":"drug","name":"Ropeginterferon alfa-2b","route":"/drugs/ropeginterferon-alfa-2b/"}],"idea":[{"id":"idea-pv-hepcidin-first","kind":"idea","name":"Hepcidin-based control as first-line treatment in low-risk polycythaemia vera","route":"/ideas/idea-pv-hepcidin-first/"}]}}